You can buy Lucitivo at the lowest price in the online pharmacy Nextgen.ooo . Tivozanib is a kinase inhibitor for the treatment of adult patients with renal cell carcinoma who have failed prior systemic therapy or whose disease has recurred.
 
Renal cell carcinoma accounts for 3% of cancer cases and is one of the 10 most common cancers in adults. The average age at diagnosis is 65 to 74 years. Tivozanib is a kinase inhibitor developed for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma after prior failure of systemic therapy. It was approved by the FDA on March 10, 2021. Tivozanib is a promising therapy for patients with RCC who have failed other treatments.
 
Vascular endothelial growth factor receptors (VEGFRs) are important targets for tyrosine kinase inhibitors that stop tumor growth. Tivozanib is a tyrosine kinase inhibitor that exerts its effects by inhibiting the phosphorylation of vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, and VEGFR-3, and also inhibits other kinases such as c-kit and platelet-derived growth factor beta (PDGFR). These actions suppress tumor growth and progression, treating renal cell carcinoma.